paradiso d'ogni cuor ♪ ♪ love ♪ is a many splendored thing ♪ come il sole piu del sole ♪ ♪ tutti ci illumina i nostri cuor ♪ ♪ amore ♪ ♪ meraviglioso amor ♪ ♪ vive d'ombra e da la luce ♪ ♪ tormenta e pure pace ♪ ♪ inferno e paradiso ♪ ♪ d'ogni cuor ♪ ♪ si ♪ ♪ quest'amore splendido ♪ ♪ come il sole piu del sole ♪ ♪ tutti ci illumina ♪ ♪ e'qualcosa di irreale che ♪ ♪ incatena i nostri cuor ♪ ♪ amore ♪ ♪ meraviglioso ♪ ♪ amor ♪ [ applause ] thank you very much. -you know, every one of these songs that, uh, we picked to sing are, just hearing them live one after another is just magnificent. it really is. bravo, andrea. -that's very kind of you, david. -amazing. you know, it was at the 71st academy awards that a little-known italian comedian won an oscar for best actor in a film that he also directed. i can't remember his name, but he was italian -- -roberto benigni, do you remember? -roberto benigni, yes. yes. and he became very famous for his very enthusiastic acceptance speech that night. he was climbing over chairs, if you remember, stepping on steven spielberg's head, it was crazy! but as a

illumina returned the results through dr. green.elivers them on a sleek ipad app so i can explore them myself. i didn't turn out to be any of the things i dreaded so much. but i do have something to think about. it's called factor 5 liden and it means my blood clots slightly faster than other people's. >> with this mutation you have about six times the risk of another person of getting a thromboemblus in your leg and a pulmonary emblus in your leg. that sounds pretty scary. but if i tell you you started off with a risk of 1 in 1,000 and you end up with 6 in 1,000. >> it turns out a lot of the things i should be doing anyway, maintaining a healthy weight, exercising not smoking and taking walking breaks on long car and plane rides. i also received information about diseases i don't have myself but that i could pass on to my children. known as carrier testing. this is a service provided by popular consumer genetics company 23 and me as well. the last part of my report showed my pharmacogenetic profile. that shows what my genes suggest

particularly that's applied to companies like illumina.here's others like thermofisher, a major competitor last we're for $13 billion. roche is also in this. they make sequencing equipment, and then there's smaller company pacific biosciences and a bunch of others that are also competing in this space. what's really interesting is it's not totally clear how useful it is to get your genome sequenced if are you healthy. if you are sick, it makes a lot more sense, but some of the barriers to adopting this so far will you things like cost and whether it's going to get reimbursed, fda clarity. that hurt -- just the proof of how useful this is. we sat down with illumina ceo and he says the costs could go further down more than we've already seen. it's gone down to $1,400 now, and he thinks it could go below $500. take a listen to what he said. >> what we have is to begin to actually create the health economic evidence that shows that if you can manage your health through use of your genome, that you can have better outcomes, number one. you can

the leader in the market is san diego-based company illumina, whose ceo jay flatly said he expects costsntinue to come down. >> we haven't announced where we think they can get, but you know, clearly getting to the $500 genome is technologically possible and we think certainlily potential fall beyond that. >> reporter: will we see a day whefsh has their genome sequenced as a routine part of medical care in the jury is still out. but what people do know is our oundsing of what the genome brings us will only improve over time. >> it will be better ten years from now. 28 be better 20 years from now. and that is this journey we're on. it's an amazing journey. with you i'm in this for my children's children. that's really where this is going to culminate. >> reporter: for nblgs nbls i'm meg tirrell. >> and tomorrow we will follow meg on her journey as she gets her own genome sequenced. you can read more on the subject on aur website at nbr.com. >> that is "nightly business report" for tonight. i'm sharon epperson. thanks so much for watching. >> and thanks from me as well. i'm tyler mathisen.

. >> illumina preannounced in october.trades close to 50 times forward earnings with the sell-off we've seen from $250 to current levels. this was probably the best piece of news they've gotten in quite some time. the stock acting in kind. given the valuation and given the length in which this will take place, you've got to stay away from illummia here. >> would you consider genome? >> i want to know it all. lay it on. let me know. i already know i'm tall, good-looking, what else can they tell me? >>> apple ceo tim cook is sitting on more than $200 billion in cash. that we know. will the tech giant go shopping for the holidays? four names one analyst says should be on his acquisition list. much more coming up. (trader vo) i search. i research. i dig. and dig some more. because, for me, the challenge of the search... is almost as exciting as the thrill of the find. (announcer) at scottrade, we share your passion for trading. that's why we rebuilt scottrade elite from the ground up - including a proprietary momentum indicato

the illumina test is much more comprehensive. it can give you back more health information about things you may be predisposed to get at some point in your life or as the 23 and me test doesn't give you that kind of information, at least as of now. but they're both very, very interesting results. >> but it did tell you what your eye color is, right? >> yeah. although i found my eyes were green and 23 and me says i'm very unlikely to have green eyes. >> all right. meg, thank you very much. meg terrell. >> i'm in the ignorant is bliss camp. i'm not sure i want to know anything. that's my approach to going to the dentist. don't go because you don't want to find out anything bad. we're bouncing back from three days of losses. the dow is up by 113 and next week is a really big one for you, the investor. many betting on a rate hike. what will be the likely path for future hikes? we have a full playbook for you. plus -- >> today's powerhouse is home to 12 fortune 500 companies. it is nicknamed the city of lakes. and it is america's thir

vertex up 3.5%, illumina up 4%.he ibb nasdaq biotech etf up 13% for the year, that is its seventh straight year of games, qualcomm is surging on the heels of a patent license agreement with two chinese firms, that stock is up 3%. tesla another gainer also up more than 3% this after the "wall street journal" reported the company is looking to add thousands of employees in the coming year as the fight for tech talent continues in the auto industry and keeping with tech, another name we have been mentioning t amazon coming off a big holiday weekend with 3 million new prime subscribers for the third week in december that stock also up nearly 3%. back over to you. >>> kate rogers with a look at some of the movers at the nasdaq. let's show you where we stand on the major indices. in terms of s&p groups that are showing strength it is technology, healthcare and consumer discretionary. bill, utilities are faring the worst of the bunch, still higher but with those yields sharply higher, especially the two year you don't see

. >> i think i want to see it all i got it mapped from illumina, for $2900, a personal guys to my ownurns out getting it sequenced is a lot like any other medical tests, with the program you go to a doctor's office, give a family history a physical exam and blood drawn. where it's different is what we can draw have the results. this was a concern for higher risk for cancer, heart disease or alzheimer's. did i want to know? the answer for me is yes, but i discovered the results could raise just as many questions as deliver answers. >> meg joins us here. what were those answers? we're dying to find out. >> i have everything here on this thumb drive. this holds all of the ways i differ from you guys or any of other people. we're 99.9% identical. it's only in that tenth of 1% we're different. it potential can be scary or hopefully useful. what i found was sort of in between. it wasn't super scary, and wasn't necessarily super useful. it turns out i have one clinical significant finding, fact factor-five lighting. it means my blood clots slightly faster, i only have one copy of this gene,

we're talking about whole genome sequences, what illumina does.me just basically geno types, looking for the ways your genome -- you could implicated in disease, and they can't provide health information because of fda stuff. >> single mutation diseases that you would know you were predisposed to, so complicated still. i mean, that's too much information now that you can't really interpret, and you see how many false positives people get from the big, you know, 24-hour physical you get. i don't want to do that because i know they'll find something, most a false positives. you don't want that, people worry, and you don't know how the environmental interaction plays with the interplay with genetics whether you are predisposed to something. it's a mess at this point, right? >> there's a lot of risk. we talk about that all day, a great story on cnbc.com to check out. >>> oil pressure building in the markets, crude trading near six year lows, sparking swings in equity markets. we have guests here to weigh in. >>> avoiding government shutdown, negotiato